Sanofi/Regeneron's Libtayo Pivotal Data Shines In Fourth Cancer Type

Phase III Trial In Cervical Cancer Stopped Early Due To Good OS Results

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.